NEI Research News

Changes in how genes in the immune system function may result in age-related macular degeneration (AMD), the leading cause of visual impairment in older adults, based on preliminary research conducted by National Institutes of Health (NIH) investigators.

The NEI, part of the National Institutes of Health (NIH), has become the first U.S. government agency to develop a formal collaborative research and training agreement with the United Kingdom’s National Health Service (NHS).

Treating patients with severe cases of uveitis, the fifth leading cause of vision loss in the United States, either locally with eye implants or systemically with anti-inflammatory medications improved vision similarly over two years.

Scientists have found that laser therapy is equivalent to two different dosages of corticosteroid medications for treating vision loss from the blockage of small veins in the back of the eye, a condition known as branch retinal vein occlusion (BRVO).

A preliminary clinical trial, conducted by researchers at the National Institutes of Health (NIH), found that an investigational treatment for uveitis seems to have many fewer side effects than existing therapies

In a small preliminary study, researchers at the National Institutes of Health (NIH) have discovered a possible new treatment for uveitis, a potentially blinding eye disease.

Researchers at the National Institutes of Health (NIH) have discovered a substance that allows people with uveitis, a potentially blinding eye disease, to stop or reduce the need for powerful drugs.

Over half of all people with first-time optic neuritis, a vision-impairing inflammation of the optic nerve, will eventually develop multiple sclerosis (MS).

Researchers report that donor-recipient tissue typing had no significant long-term effect on the success of corneal transplantation in a nationwide clinical study of over 400 patients at high risk for rejection.